Viewray (NASDAQ:VRAY)‘s stock had its “neutral” rating reiterated by research analysts at B. Riley in a note issued to investors on Wednesday, BenzingaRatingsTable reports. They presently have a $5.00 target price on the stock, down from their prior target price of $9.00. B. Riley’s target price points to a potential upside of 12.61% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley set a $5.00 price objective on Viewray and gave the company a “hold” rating in a report on Monday, August 12th. Piper Jaffray Companies set a $6.00 target price on Viewray and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Zacks Investment Research cut Viewray from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 16th. Oppenheimer began coverage on Viewray in a research report on Tuesday, October 22nd. They issued an “outperform” rating and a $7.00 target price for the company. Finally, BidaskClub upgraded shares of Viewray from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $6.60.

NASDAQ:VRAY opened at $4.44 on Wednesday. Viewray has a fifty-two week low of $2.12 and a fifty-two week high of $9.76. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.58 and a current ratio of 3.70. The company has a 50 day moving average price of $2.83 and a 200 day moving average price of $5.55. The stock has a market capitalization of $441.36 million, a P/E ratio of -4.53 and a beta of 1.09.

Viewray (NASDAQ:VRAY) last announced its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.06. Viewray had a negative return on equity of 75.41% and a negative net margin of 110.61%. The company had revenue of $20.90 million for the quarter, compared to analyst estimates of $20.66 million. During the same quarter in the previous year, the company earned ($0.39) earnings per share. The firm’s quarterly revenue was up 18.1% compared to the same quarter last year. Research analysts forecast that Viewray will post -1.13 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Usca Ria LLC acquired a new stake in shares of Viewray in the third quarter valued at $28,000. Stifel Financial Corp acquired a new position in Viewray during the 3rd quarter worth $39,000. Bank of Montreal Can grew its stake in Viewray by 4,390.1% during the 2nd quarter. Bank of Montreal Can now owns 5,882 shares of the company’s stock worth $52,000 after purchasing an additional 5,751 shares in the last quarter. Raymond James Trust N.A. purchased a new stake in Viewray during the 3rd quarter worth about $86,000. Finally, Allworth Financial LP increased its holdings in Viewray by 587.8% during the 3rd quarter. Allworth Financial LP now owns 32,594 shares of the company’s stock worth $95,000 after purchasing an additional 27,855 shares during the period.

Viewray Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Read More: Google Finance Portfolio

Analyst Recommendations for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with's FREE daily email newsletter.